Why are major pharmaceutical businesses on the way to China?

From artificial intelligence to defense industries, China has recorded remarkable achievements such as “Deep Seck” this year, in a renewed claim that it is no longer a factory for the world, but also a powerful force to technically compete with the United States. These lights today expanded to the biotechnology sector. At the end of May, Pfizer agreed to pay a record amount of $ 1.25 billion in advance to license an experimental agent to treat cancer of the 3sbio company in Senyang and invested $ 100 million in the shares of the company on the Hong Kong Stock Exchange. Only two weeks later, Bristol -Myers Squibb announced that it would pay $ 1.5 billion unconditional dollars to BionTech to license a drug similar to cancer, and he acquired from the ‘BunetTek’, which acquired the Chinese company by the Chinese company at the end of last year. An investment centiasm has become more and more pharmaceutical businesses in Chinese biotechnology businesses, a force found on the traditional scene. The last two pavilions open the way for “Pistar” and “Bristol merspop” to compete with “Keytruda” by “Merck & Co”, which is the best-selling drug in the world. The “SRB” medicine depends on the same therapeutic approach that the Chinese company “Akeso” developed in one of the clinical trials and set out on “Kethroda”. The US company “Summit Therapics” has acquired the rights of this treatment at the end of 2022 for half a billion in advance. These billionaire transactions have set fire to the enthusiasm of investors and bankers, as the ‘Hangh Biotechnology’ index has jumped by 60% since the beginning of the year, compared to a 6.5% decline in the Standard & Poor Piotics index. Also read: The Chinese biotechnology sector is valued at $ 220 billion, but Trump’s policy also predicts indicators that the frequency of acceleration of transactions and the growing momentum of biotechnology sector in China will not only be a passing wave, but rather a continuous orientation that mainly pushes the economic policy of US President Donald Trump. With Trump threatening to lower the prices of medicines available by a ‘59% and more ‘prescription, in addition to expected deductions in the’ Medicid ‘and’ Medicir ‘programs within its large tax and spending project, large pharmaceutical businesses come into the risk of their profits. This can cause these businesses to reduce the research and developmental expenses that they undertake internally, and to go to China, where human experiences in the early stages are cheaper and easier to implement, despite the agreements in terms of safety standards. To date, the biotechnology sector is still relatively immune to the customs laid down, making it a safe haven in the eyes of world investors. While rare soil minerals and Boeing aircraft are used as a negotiation printing card, Beijing holds the public health sector outside these accounts, but it continues to import US medical products, including Lorbrena, to treat lung cancer of “Pfizer” and the Gardasil vaccine to prevent “Merck” cervical cancer. This good relationship with Beijing enables major pharmaceutical businesses to enter into licensing agreements with local partners in the Chinese market. Also read: China also rejected the effects of Trump’s policy on scientific research. International pharmaceutical businesses and adventurous capital funds may try to buy shares in Chinese biotechnology businesses, just as “Pfizer” did last month. In light of the decline in financing the sector, especially in China, Startups is having trouble developing their medication independently, which leads to them demanding large preliminary payments in exchange for the granting of licenses, which provides greater negotiation capacity to close transactions on comfortable conditions. The abundance of engineers, but what is the benefit of innovation without human skills? China’s profits of engineers “offered him the most in the coming years, in light of the strict policy of the White House, which promises to cancel” visas “for Chinese students in” sensitive specializations “. The number of Chinese students in the United States fell by 22% compared to its peak before the pandem could choose more in China and start in the United States.” Securities “.